Ad5F35-LMP1/LMP2-transduced autologous dendritic cells(National Cancer Centre of Singapore Pte)(Ad5F35-LMP1/LMP2-transduced autologous dendritic cells(National Cancer Centre of Singapore Pte))

概要

基本信息

药物类型

治疗性疫苗、树突状细胞疫苗

别名-

靶点

LMP1 x LMP2

作用方式

调节剂

作用机制

LMP2调节剂(EBV潜伏膜蛋白2调节剂)、潜伏膜蛋白1调节剂

治疗领域

肿瘤口颌疾病耳鼻咽喉疾病+ [1]

在研适应症-

非在研适应症

鼻咽癌

原研机构

National Cancer Centre of Singapore Pte Ltd.

在研机构-

非在研机构

National Cancer Centre of Singapore Pte Ltd.

权益机构-

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 Ad5F35-LMP1/LMP2-transduced autologous dendritic cells(National Cancer Centre of Singapore Pte) 相关的临床试验

NCT00589186

/ Unknown status临床2期IIT

Phase II Clinical Trial of Tumour Vaccination By Intradermal Delivery of Autologous Dendritic Cells Transduced With Adenoviral Vector (AD5F35) Expressing Latent Membrane Protein-1 (LMP-1) and Latent Membrane Protein-2 (LMP-2) Genes in Combination With Celecoxib in Patient With Metastatic Nasopharyngeal Carcinoma

RATIONALE: Vaccines made from a gene-modified virus and a person's dendritic cells may help the body build an effective immune response to kill tumor cells. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with celecoxib may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving vaccine therapy together with celecoxib works in treating patients with metastatic nasopharyngeal cancer.

开始日期2007-11-01

申办/合作机构

National Cancer Centre of Singapore Pte Ltd.

100 项与 Ad5F35-LMP1/LMP2-transduced autologous dendritic cells(National Cancer Centre of Singapore Pte) 相关的临床结果

登录后查看更多信息

100 项与 Ad5F35-LMP1/LMP2-transduced autologous dendritic cells(National Cancer Centre of Singapore Pte) 相关的转化医学

登录后查看更多信息

100 项与 Ad5F35-LMP1/LMP2-transduced autologous dendritic cells(National Cancer Centre of Singapore Pte) 相关的专利（医药）

登录后查看更多信息

100 项与 Ad5F35-LMP1/LMP2-transduced autologous dendritic cells(National Cancer Centre of Singapore Pte) 相关的药物交易

登录后查看更多信息